» Articles » PMID: 20708085

Humoral and Cellular Immunity to Primary H1N1 Infection in Patients with Hematologic Malignancies Following Stem Cell Transplantation

Abstract

Limited data are available on immunologic responses to primary H1N1 infection in patients with hematologic malignancies. We present a prospective, case-surveillance study of such patients with real-time polymerase chain reaction (RT-PCR) confirmed H1N1-influenza who presented to our institution between September 2009 and January 2010. Ninety-two patients presented with influenza-like symptoms, and 13 had H1N1 infection confirmed by RT-PCR, including 4 allogeneic stem cell transplant recipients (1 with acute myelogenous leukemia, 1 with chronic lymphoblastic leukemia [CLL], 1 with non-Hodgkin lymphoma, and 1 with chronic myelogenous leukemia), 5 patients with multiple myeloma following autologous stem cell transplantation, 1 patient with multiple myeloma perimobilization, 2 patients with NHL post chemotherapy, and 1 patient with CLL. All 13 patients required hospitalization. Six (43%) were admitted to the intensive care unit (ICU), of whom 4 (67%) died. We evaluated B cell and T cell responses to H1N1 infection prospectively in these patients compared with those in 4 otherwise healthy controls. Within 12 weeks of diagnosis, only 6 of 11 patients developed seropositive antibody titers as measured by hemagglutination-inhibition or microneutralization assays, compared with 4 of 4 controls. H1N1-specific T cells were detected in only 2 of 8 evaluable patients compared with 4 of 4 controls. H1N1-specific T cells were functional, capable of producing interferon γ, tumor necrosis factor α, and CD107a mobilization. Furthermore, CD154 was up-regulated on CD4(+) T cells in 3 of 4 controls and 2 of 2 patients who had both B cell and T cell responses to H1N1. Post-H1N1 infection, 5 of 8 patients developed seasonal influenza-specific T cells, suggesting cross-reactivity induced by H1N1 infection. These data offer novel insights into humoral and cell-mediated immunologic responses to primary H1N1 infection.

Citing Articles

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.

de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A Blood. 2013; 122(2):227-38.

PMID: 23719297 PMC: 5726329. DOI: 10.1182/blood-2012-11-465039.


Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.

Kobold S, Luetkens T, Bartels B, Cao Y, Hildebrandt Y, Sezer O Clin Dev Immunol. 2012; 2012:134081.

PMID: 22481961 PMC: 3310258. DOI: 10.1155/2012/134081.


Long term immune responses to pandemic influenza A/H1N1 infection in solid organ transplant recipients.

Baluch A, Humar A, Egli A, Gubbay J, Lisboa L, Wilson L PLoS One. 2011; 6(12):e28627.

PMID: 22194870 PMC: 3237471. DOI: 10.1371/journal.pone.0028627.


Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.

Roll D, Ammer J, Holler B, Salzberger B, Schweiger B, Jilg W Infection. 2011; 40(2):153-61.

PMID: 22038110 PMC: 7102312. DOI: 10.1007/s15010-011-0206-5.


Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients.

Renaud C, Campbell A Curr Opin Infect Dis. 2011; 24(4):333-43.

PMID: 21666460 PMC: 3210111. DOI: 10.1097/QCO.0b013e3283480440.